Ocular Therapeutix (OCUL) Current Assets (2013 - 2026)

Ocular Therapeutix's Current Assets history runs 14 years deep, the most recent figure standing at $706.0 million for Q1 2026.

• On a quarterly basis, Current Assets rose 82.1% year-over-year to $706.0 million in Q1 2026; TTM through Mar 2026 was $706.0 million, a 82.1% increase from a year earlier, with the FY2025 full-year figure at $782.1 million, up 77.36% from the prior year.
• Current Assets eased to $706.0 million in Q1 2026 per OCUL's latest filing, from $782.1 million in the prior quarter.
• Across five years, Current Assets topped out at $782.1 million in Q4 2025 and bottomed at $100.7 million in Q2 2023.
• The 5-year median for Current Assets is $387.0 million (2025), against an average of $342.4 million.
• Across the five-year window, Current Assets slumped 38.64% in 2023 and soared 395.06% in 2024, its largest moves.
• Year by year, Current Assets stood at $129.6 million in 2022, then surged by 79.16% to $232.2 million in 2023, then soared by 89.89% to $441.0 million in 2024, then surged by 77.36% to $782.1 million in 2025, then retreated by 9.73% to $706.0 million in 2026.
• Per Business Quant, the three latest OCUL Current Assets figures stand at $706.0 million (Q1 2026), $782.1 million (Q4 2025), and $387.0 million (Q3 2025).